Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43379
UPID:
WDR62_HUMAN
Alternative names:
-
Alternative UPACC:
O43379; Q63HP9; Q659D7; Q8NBF7; Q96AD9
Background:
WD repeat-containing protein 62 (WDR62) is pivotal in cerebral cortical development, influencing neuronal proliferation and migration. It is part of a complex mechanism involving CEP152, CDK5RAP2, and CEP63 that is crucial for centriole duplication, a process essential for cell division and development.
Therapeutic significance:
WDR62 is linked to Microcephaly 2, a disorder marked by significant brain development issues and intellectual disability. Understanding WDR62's role could lead to breakthroughs in treating or managing this condition, highlighting its therapeutic potential.